Which Risk Model Better Identifies High-Risk Smoldering MM?

Published Date: 28 Apr 2026

A cohort study compares the distribution and progression risk among individuals classified as having high-risk smoldering multiple myeloma by the AQUILA trial inclusion criteria vs 2/20/20 risk model.

Read Full News

Latest News

Annual Cancer Report Highlights Advances, Funding Threats

A yearly report from the American Association for Cancer Research lauds recent breakthroughs but warns on threatened federal funding changes.

Does Telenursing Improve QOL in Breast Cancer?

A meta-analysis assesses the effect of nurse-led telenursing on the quality of life in women with breast cancer.

Long-Term Results Favor Acalabrutinib Combo in MCL

The 50-month follow-up of the ECHO trial underscores greater benefits with concurrent vs sequential addition of acalabrutinib to bendamustine and rituximab.

First-Line Combo Therapies Best Chemo Alone in NSCLC Trials

New phase 3 data add to a growing number of EGFR-directed first-line options for advanced NSCLC with EGFR exon 20 insertions.

3D Mammography Improves Long-Term Cancer Risk Prediction

Researchers develop and validate a deep learning model using longitudinal 3D tomosynthesis examinations to predict individualized 5-year risk for breast cancer.

Osimertinib's OS Benefit in Resected NSCLC Persists 8 Years

Even years after treatment ends, adjuvant osimertinib brings an overall survival benefit to patients with resected EGFR-mutated lung cancer.

Todays Updates

Verekitug's Quarterly Dosing Cuts Asthma Burden, With Michael Wechsler, MD Michael Wechsler, MD, MSc

Wechsler discusses why less frequent dosing matters to patients with severe asthma, plus VALIANT's safety profile and what's next for the field.

Tozorakimab Cuts COPD Mucus Plugging, With George Washko, MD

Tozorakimab Cuts COPD Mucus Plugging, With George Washko, MD

Chronic Proton Pump Inhibitor Use Linked to More Asthma Exacerbations

Chronic Proton Pump Inhibitor Use Linked to More Asthma Exacerbations

FDA Approves Autoinjector for Self-Administered Zilucoplan in Generalized Myasthenia Gravis Marco Meglio

Adults with generalized myasthenia gravis who are anti-acetylcholine receptor antibody positive now have a second self-administration option for the complement inhibitor zilucoplan.

Levacetylleucine Shows Sustained Benefit at 3 Years in Niemann-Pick Disease Marco Meglio

Three-year extension data from the phase 3 IB1001-301 trial show levacetylleucine slowed disease progression in both adults and children with Niemann-Pick disease type C.

Recognizing Familial Chylomicronemia Syndrome in the APOC3 Era

Recognizing Familial Chylomicronemia Syndrome in the APOC3 Era

Todays Updates

Verekitug's Quarterly Dosing Cuts Asthma Burden, With Michael Wechsler, MD Michael Wechsler, MD, MSc

Wechsler discusses why less frequent dosing matters to patients with severe asthma, plus VALIANT's safety profile and what's next for the field.

Tozorakimab Cuts COPD Mucus Plugging, With George Washko, MD

Tozorakimab Cuts COPD Mucus Plugging, With George Washko, MD

Chronic Proton Pump Inhibitor Use Linked to More Asthma Exacerbations

Chronic Proton Pump Inhibitor Use Linked to More Asthma Exacerbations

FDA Approves Autoinjector for Self-Administered Zilucoplan in Generalized Myasthenia Gravis Marco Meglio

Adults with generalized myasthenia gravis who are anti-acetylcholine receptor antibody positive now have a second self-administration option for the complement inhibitor zilucoplan.

Levacetylleucine Shows Sustained Benefit at 3 Years in Niemann-Pick Disease Marco Meglio

Three-year extension data from the phase 3 IB1001-301 trial show levacetylleucine slowed disease progression in both adults and children with Niemann-Pick disease type C.

Recognizing Familial Chylomicronemia Syndrome in the APOC3 Era

Recognizing Familial Chylomicronemia Syndrome in the APOC3 Era

Latest News

A yearly report from the American Association for Cancer Research lauds recent breakthroughs but warns on threatened federal funding changes.

A meta-analysis assesses the effect of nurse-led telenursing on the quality of life in women with breast cancer.

The 50-month follow-up of the ECHO trial underscores greater benefits with concurrent vs sequential addition of acalabrutinib to bendamustine and rituximab.

New phase 3 data add to a growing number of EGFR-directed first-line options for advanced NSCLC with EGFR exon 20 insertions.

Researchers develop and validate a deep learning model using longitudinal 3D tomosynthesis examinations to predict individualized 5-year risk for breast cancer.

Even years after treatment ends, adjuvant osimertinib brings an overall survival benefit to patients with resected EGFR-mutated lung cancer.

News All Time

Tissue-Free ctDNA Predicts Recurrence in Early Breast Cancer

Researchers analyzed plasma samples collected from 313 patients with early breast cancer approximately 2 years after they had completed adjuvant chemotherapy.

SBRT Plus Atezolizumab Shows No Benefit in Inoperable NSCLC

For patients with early-stage, inoperable lung cancer, adding atezolizumab to standard radiotherapy boosts toxicity, not survival.

TKI Discontinuation Feasible After ALL Treatment

In patients with first- or second-line Philadelphia-positive B-cell acute lymphoblastic leukemia, favorable outcomes are observed with discontinuation of ponatinib.

Sevabertinib Approved for First-Line Mutated NSCLC

The oral HER2 TKI was previously given accelerated approval in the second line for the indication.

A New PARADIGM? Azacitidine-Venetoclax Tops Chemo in AML

The less-intensive drug combination outperforms standard induction chemotherapy in fit patients with acute myeloid leukemia.

FDA Approves Camizestrant for ESR1-Mutated Breast Cancer

The accelerated approval enables an endocrine therapy switch when the ESR1 resistance mutation is detected, rather than waiting for evidence of disease progression.

Talc Powder Not Linked to Lung Cancer in Women

A study of US women finds no connection between talc powder use and lung cancer, though subgroup findings leave questions open.

Saturated Fat Tied to Worse Survival After Prostate Cancer

The association is driven by higher rates of death from cardiovascular disease and other cancers over 13 years.

Medication Self-Injection Embraced by Breast Cancer Patients

Women with breast cancer show interest in self-injecting their medication.

Can 80 Gy Radiation Boost Survival in Prostate Cancer?

A modest increase in radiation dose improves progression-free survival over 10 years among men with high-risk prostate cancer — but the overall survival benefits found in a French trial are uncertain.

Low Awareness of How to Spot Rare Breast Cancer Identified

Researchers survey US adults to assess their knowledge of inflammatory breast cancer.

Remote CBT for Insomnia Improves Symptoms During Chemo

A new randomized trial strengthens the case for managing cancer-related insomnia with cognitive-behavioral therapy.

Long-Acting Interferon Therapy Approved for ET

Ropeginterferon alfa-2b is designed to provide durable disease control.

Thymus Radiation Exposure Tied to Worse Lung Cancer Outcomes

The thymus is not routinely considered during thoracic radiotherapy planning, but new findings suggest that may need to change.

FDA Approves Rusfertide for Polycythemia Vera

Adding rusfertide to standard-of-care treatment cut phlebotomy rates by more than half in the phase 3 VERIFY trial.

Black Canadians Face Multiple Barriers to Blood Donation

Barriers to blood donations from Black people in Canada are rooted in racism and restrictive policies.

Recommended News For You

Black Canadians Face Multiple Barriers to Blood Donation

Novel Drugs Boost Immunotherapy Activity in Resectable Lung Cancer

Recurrent UTIs impact eGFR in children with vesicoureteral reflux

According to research, hospitals can save money and help cancer patients by implementing a basic intervention.

Toxic fungus from King Tutankhamun's tomb yields cancer-fighting compounds—new study

Survivors of childhood brain cancer are more likely to be held back in school

First-Line Combo Therapies Best Chemo Alone in NSCLC Trials

Recommended Articles For You

A Comprehensive Guide to Carcinoma in Situ: Types, Risks, and Preventive Measures 

Intensive Care Strategies for Hyperacute Oncologic Emergencies 

Prevention of Heparin-Induced Thrombocytopenia Complications Through Platelet Activation Signature Monitoring 

Targeted Degradation in Breast Cancer: Mechanisms, Clinical Applications, and Future Perspectives 

Whats more on Hidoc Dr.

Medical Updates
KOL Videos
Surveys
Events

Daily news to keep you up to date

Gain valuable insights with our in-depth KOL Video discussions

Participate and win cash vouchers

Get updates on the latest events happening around the world
Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Which Risk Model Better Identifies High-Risk Smoldering MM?

2.

Study Linking Fruits, Veggies to Lung Cancer Raises Eyebrows

3.

Imfinzi + Imjudo, EU approved for patients with advanced lung cancer and non-small cell lung cancer: AstraZeneca

4.

The Cherenkov color image shows the possibility of improving the quality of radiation therapy.

5.

Bayer is transforming pharmaceutical research into women's health

1.

Refining AML Survival: Prognostic Factors, Therapies, and Stem Cell Strategies Reviewed

2.

Multidisciplinary Insights into Diagnosis, Management, and Outcomes in Oncology

3.

Hematologic Cytomorphology: From Microscopy to Molecular Diagnostics

4.

Biomimetic Nanovesicles Target Senescent-Escape Cancer Stem Cells in Breast Cancer

5.

Patient Management Following Organ-Preserving Cancer Interventions

1.

International Conference on Innovations in Critical Care for Oncology and Cardiology

2.

International Conference on Oncology, Cardiology and Critical Care Policy

3.

International Conference on Oncology, Cancer Prevention and Public Health

4.

International Conference on Cancer Nursing and Rehabilitation Strategies

5.

International Conference on Best Practices in Oncology, Cardiology and Critical Care

1.

Managing Common Side Effects During Cancer Treatment

2.

An Eagles View - Evidence-based Discussion on Iron Deficiency Anemia- Panel Discussion

3.

Pazopanib Takes Center Stage in Managing Renal Cell Carcinoma - Part V

4.

Navigating the Complexities of Ph Negative ALL - Part XII

5.

Cancer screening: Test that can help detect cancer early

Fastest Growing Medical Platform for Doctors

Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801

Phone :
+1-415-463-3094

Email :
anishagadia@hidoc.co

Quick Links

Drug DatabaseDrug InteractionDiseases Database
KOL VideosKnowledge HubQuizzes
Medical UpdatesEventsAbout Us

© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
Home
Profile
Login
bot